These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 15705170)

  • 1. Synthesis and biological activity of GnRH antagonists modified at position 3 with 3-(2-methoxy-5-pyridyl)-alanine.
    Samant MP; Miller C; Hong DJ; Koerber SC; Croston G; Rivier CL; Rivier JE
    J Pept Res; 2005 Feb; 65(2):284-91. PubMed ID: 15705170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel gonadotropin-releasing hormone antagonists with substitutions at position 5.
    Samant MP; Hong DJ; Croston G; Rivier C; Rivier J
    Biopolymers; 2005; 80(2-3):386-91. PubMed ID: 15614806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II.
    Samant MP; Gulyas J; Hong DJ; Croston G; Rivier C; Rivier J
    J Med Chem; 2005 Jul; 48(15):4851-60. PubMed ID: 16033265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Betidamino acid scan of the GnRH antagonist acyline.
    Jiang G; Miller C; Koerber SC; Porter J; Craig AG; Bhattacharjee S; Kraft P; Burris TP; Campen CA; Rivier CL; Rivier JE
    J Med Chem; 1997 Nov; 40(23):3739-48. PubMed ID: 9371239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, in vivo and in vitro biological activity of novel azaline B analogs.
    Samant MP; Gulyas J; Hong DJ; Croston G; Rivier C; Rivier J
    Bioorg Med Chem Lett; 2005 Jun; 15(11):2894-7. PubMed ID: 15911275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)- 6-methylpyrimidin-2,4-dione (NBI 42902) as a potent and orally active antagonist of the human gonadotropin-releasing hormone receptor. Design, synthesis, and in vitro and in vivo characterization.
    Tucci FC; Zhu YF; Struthers RS; Guo Z; Gross TD; Rowbottom MW; Acevedo O; Gao Y; Saunders J; Xie Q; Reinhart GJ; Liu XJ; Ling N; Bonneville AK; Chen T; Bozigian H; Chen C
    J Med Chem; 2005 Feb; 48(4):1169-78. PubMed ID: 15715483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid suppression of plasma testosterone levels and tumor growth in the dunning rat model treated with degarelix, a new gonadotropin-releasing hormone antagonist.
    Princivalle M; Broqua P; White R; Meyer J; Mayer G; Elliott L; Bjarnason K; Haigh R; Yea C
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1113-8. PubMed ID: 17179469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Degarelix for prostate cancer.
    Doehn C; Sommerauer M; Jocham D
    Expert Opin Investig Drugs; 2009 Jun; 18(6):851-60. PubMed ID: 19453267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban.
    Manning M; Cheng LL; Stoev S; Wo NC; Chan WY; Szeto HH; Durroux T; Mouillac B; Barberis C
    J Pept Sci; 2005 Oct; 11(10):593-608. PubMed ID: 15880385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing subcutaneous injection of the gonadotropin-releasing hormone receptor antagonist degarelix.
    Barkin J; Burton S; Lambert C
    Can J Urol; 2016 Feb; 23(1):8179-83. PubMed ID: 26892063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer.
    Van Poppel H; Tombal B; de la Rosette JJ; Persson BE; Jensen JK; Kold Olesen T
    Eur Urol; 2008 Oct; 54(4):805-13. PubMed ID: 18538469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues.
    Tornøe CW; Agersø H; Senderovitz T; Nielsen HA; Madsen H; Karlsson MO; Jonsson EN
    Br J Clin Pharmacol; 2007 Jun; 63(6):648-64. PubMed ID: 17096678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and structure-activity relationships of thieno[2,3-b]pyridin-4-one derivatives as a novel class of potent, orally active, non-peptide luteinizing hormone-releasing hormone receptor antagonists.
    Imada T; Cho N; Imaeda T; Hayase Y; Sasaki S; Kasai S; Harada M; Matsumoto H; Endo S; Suzuki N; Furuya S
    J Med Chem; 2006 Jun; 49(13):3809-25. PubMed ID: 16789738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo characterization of a novel GnRH (gonadotropin-releasing hormone) antagonist, LXT-101, in normal male rats.
    Chi X; Zhou W; Cheng J; Zhang Y; Liu K
    Regul Pept; 2006 Sep; 136(1-3):122-9. PubMed ID: 16828893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III.
    Samant MP; Hong DJ; Croston G; Rivier C; Rivier J
    J Med Chem; 2006 Jun; 49(12):3536-43. PubMed ID: 16759096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a novel, orally active, small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.
    Li H; Anderes KL; Kraynov EA; Luthin DR; Do QQ; Hong Y; Tompkins E; Sun ET; Rajapakse R; Pathak VP; Christie LC; Feng J; Vazir H; Castillo R; Gregory ML; Castro M; Nared-Hood K; Paderes G; Anderson MB
    J Med Chem; 2006 Jun; 49(11):3362-7. PubMed ID: 16722655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of new gonadotrophin-releasing hormone partial agonists.
    Leaños-Miranda A; Ulloa-Aguirre A; Cervini LA; Janovick JA; Rivier J; Conn PM
    J Endocrinol; 2006 Jun; 189(3):509-17. PubMed ID: 16731782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GnRH analogues--agonists and antagonists.
    Padula AM
    Anim Reprod Sci; 2005 Aug; 88(1-2):115-26. PubMed ID: 15955640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of real-time PCR assays in the study of gonadotropin subunits, follistatin and prolactin genes expression in the porcine anterior pituitary during the preovulatory period.
    Lisowski P; Robakowska-Hyzorek D; Blitek A; Kaczmarek MM; Gajewska A; Kochman H; Zwierzchowski L; Ziecik AJ; Kochman K
    Neuro Endocrinol Lett; 2008 Dec; 29(6):958-64. PubMed ID: 19112413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial comment on: Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker-results from a 1-yr, multicentre, randomised, phase 2 dose-finding study in the treatment of prostate cancer.
    Whelan P
    Eur Urol; 2008 Oct; 54(4):815. PubMed ID: 18538468
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.